Search

everythinglearnresearchcommunity

for

Search:↓

KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

Hair systems are a popular solution for hair loss, offering impressive transformations with manageable maintenance and cost. Some users prefer hair systems over medications like Minoxidil or Finasteride, while others express concerns about the permanence and visibility of these systems.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

A 20-year-old is using dutasteride, minoxidil, finasteride with stemoxydine, alfatradiol, ketoconazole shampoo, and dermapen for hair loss and is considering mixing these treatments to save time. They are also contemplating a hair transplant that requires 3500 grafts.

User has been using topical finasteride and minoxidil since May, previously used a spray version since January. They are seeing vellus hairs and have added weekly microneedling to their routine.

The user had a hair transplant and uses oral minoxidil, a red laser therapy helmet, fish oil, collagen, and sardines for hair thinning but avoids finasteride due to side effect concerns. Many suggest these methods may not be effective long-term without a DHT blocker.

A user shared their experience with a hair transplant surgery in India, involving 3,500 grafts, and expressed satisfaction with the results and cost. The post received mixed reactions, with some users questioning the authenticity of the graft count and results, while others praised the outcome.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

A user shared an 18-month update on their crown hair transplant, performed by Jason Sorgi at Boston Hair Restoration, expressing satisfaction with the results. They continue to use oral minoxidil and finasteride to maintain hair health.

The conversation is about trying Keratin Microsphere products for hair loss, specifically SAF 100 Pro, but no noticeable results were observed. The user also mentioned using a Hairclub wand.

The user is using a self-made topical mix of finasteride and minoxidil foam for hair loss, experiencing solid regrowth in the frontal area and mild improvement at the crown, but still shedding. They previously used oral finasteride and dutasteride but stopped due to side effects, and are seeking advice on when shedding might stabilize with the topical treatment.

Creating a liposomal gel with Pyrilutamide for hair loss to reduce systemic effects, similar to Xyon's gel. The discussion includes concerns about ingredient sourcing and the benefits of targeted topical treatments.

User mixed RU58841 with stemoxydine, experienced no side effects. Mixing RU58841 with fluridil caused chest tightness.

A dental technician claims malocclusion causes pattern hair loss due to poor scalp circulation. Users debate this, noting treatments like finasteride, minoxidil, and microneedling focus on DHT and blood flow.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

HMI-115, a potential treatment for hair loss that has been reported to produce significant regrowth in bald areas. It is the closest thing to a cure currently available and has raised hope that it could make hair transplants obsolete.

The user experienced no improvement in hair loss with finasteride and minoxidil but had side effects. They plan to add wounding, scalp massage, vitamin K, and taurine supplements to their regimen and seek feedback on these additions.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

The conversation discusses a user's positive experience with hair regrowth using topical finasteride, minoxidil, and microneedling after 2.5 months, noting initial shedding but improved hair density, especially at the temples, possibly eliminating the need for a hair transplant. The user is satisfied with the current treatment and is hesitant to try the experimental drug RU58841, hoping the current routine will suffice for further improvements.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

A user who experienced positive results from using finasteride and dutasteride to treat their hair loss, with 2000 grafts being transplanted in the temples area for further improvement. They also discussed cost and other treatments such as minoxidil.

The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.

Chinese researchers have successfully created hair follicles in vitro, potentially offering unlimited hair for transplantation and a cure for hair loss. They plan to test these follicles in vivo on human scalps.

The user is dissatisfied with their hair transplant results from Asli Tarcan, citing poor donor area management and insufficient graft density. They advise against opting for cheaper procedures and express hope for future hair cloning solutions.

KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.